Skip to main content
Fig. 7 | BMC Medical Genomics

Fig. 7

From: Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer

Fig. 7

IAPs Determine Sensitivity to Apoptosis Inhibitors from preclinical cell line data. From the Genomics of Drug Sensitivity in Cancer (GDSC) database, we identified 8 drugs targeting the apoptosis pathway involving targets of BCL-2, BIRC5, Procaspases, RIPK1, TRAIL, and XIAP. The spectrum of association between IAPs expression and apoptosis targets was quite diverse, with the expression of BIRC3, BIRC5, BIRC6, BIRC7 mostly associated with sensitivity to BCL-2 inhibitors while the expression of XIAP and BIRC2 mostly associated with resistance. As an example, green dotted box represented LUSC cell lines with high XIAP expression being resistant to obatoclax mesylate, a BCL-2 inhibitor. Red dotted box represented obatoclax mesylate was sensitive to LIHC cell line with high BIRC5 expression

Back to article page